Document:

<Page>

                                                               EXHIBIT 10.29

                             COLLABORATION AGREEMENT
                                     BETWEEN
                        VARIAGENICS, INC ("VARIAGENICS")
                                       AND
                         BRUKER DALTONICS, INC ("BDAL")

OBJECTIVE

Variagenics and BDAL wish to collaborate technically and commercially in the
application of MALDI-TOF mass spectrometry to pharmacogenomics. In particular,
Variagenics wishes to purchase certain mass spectrometers from BDAL for
incorporation into products to be used and or sold by Variagenics, and BDAL
wishes to grant Variagenics the right to use, market and resell such products to
Variagenics' customers and partners.

TERM

Once signed by both parties, this Agreement shall be valid until March 31, 2003
or until terminated by either party for any other reason with (90) days written
notice. Notwithstanding the foregoing, in the event of termination of the
Agreement, BDAL shall remain obligated to fill any outstanding orders which have
been placed by Variagenics and accepted by BDAL. Thereafter, this Agreement is
renewable for additional one year periods by mutual written consent.

PRODUCT DEFINITION

The mass spectrometer which may be resold by Variagenics as an authorized
OEM-dealer for BDAL, is a BDAL autoflex -Registered Trademark- MALDI-TOF, which
may have additional software or target applications tailored to the demands of
Variagenics, described in more detail in the list price quotation shown in
Attachment A . Variagenics shall have the right to co-label the BDAL MALDI-TOF
instrument installed at the Variagenics' customer site with its own brand names.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

OEM PRICING AND VOLUME DISCOUNTS

The following OEM pricing and annual volume discount structure will apply to
future Variagenics orders for autoflex systems:

<Table>
<Caption>
               Quantity (p.a.)                OEM discount

<S>                                           <C>
                    [___]                         [__]%

                    [___]                         [__]%

                    [____]                        [__]%

                    [___]                         [___]%
</Table>

"Quantity" is the number of autoflex systems, ordered by Variagenics, and
accepted by BDAL, in a given calendar year, for which a down payment of N30
after order placement has been received by BDAL.

"OEM Discount" is the percentage discount off the U.S. list price quotation
given in Attachment A. This U.S. list price is valid for the 1 year term
extension of the Agreement (ie to March 31st 2003) and any changes will occur
only by mutual written consent upon agreement renewal.

For each calendar year, the initial OEM discount is [__]% but if Variagenics
orders more than [__] or reaches the other trigger-points, in any calendar year,
the relevant higher quantity OEM discount will be applied to the previously
ordered systems retroactively. This volume discount method will apply for the
calendar year 2002. For systems ordered by Variagenics for in-house use and
development, the highest OEM discount will apply providing that the system is
not resold within 2 years after delivery. All pricing is understood as EX-WORKS,
BDAL factory in Billerica, USA (or Leizpeg, Germany for European deliveries) and
does not include import duty, or any country local sales tax, VAT,
Mehrwertsteuer, or similar tax.

PAYMENT TERMS

For each autoflex system, the payment terms are as follows:

       [__]% deposit N30 after order placement
       [__]% N30 after first deleivery to either Variagenics or final customer
       [__]% N30 upon installation and acceptance at final customer site
       (Provided, however, that if the system is first installed at
       Variagenics, then [__]% will be due N30 after acceptance at Variagenics,
       and the final [__]% will be due N30 after acceptance at the final
       customer site.)

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

FORECASTS AND DELIVERIES

For each new calendar year, Variagenics, at its own discretion, may provide BDAL
with a realistic volume forecast for the next calendar year at least four months
before the end of the previous year. This forecast shall be reviewed and updated
by Variagenics quarterly, at least 45 days before the end of each quarter.
Unless specifically stated otherwise, BDAL will plan on delivering the
forecasted autoflex systems to Variagenics at a steady flow, provided however,
that for each system Variagenics has also placed a purchase order with
corresponding down-payment at least 2 months before expected delivery. (Example:
If Variagenics forecasts 12 systems for calendar year 2002, then BDAL will
delivery one system per month)

If Variagenics orders significantly fewer (GREATER THAN 25% discrepancy)
autoflex -Registered Trademark- systems than forecasted or for any calendar year
for which Variagenics does not provide a forecast as outlined in the previous
paragraph, then the forecasting method will be abandoned as a delivery planning
tool, and deliveries will be within 3-4 months ARO (After Receipt of Order),
depending on quantity of autoflex systems ordered and also depending on BDAL's
other MALDI-TOF order and production flow.

For orders of single autoflex systems in any one month which have not been
forecasted, delivery will occur 3-4 months ARO. BDAL will also assign and hold a
delivery slot for up to one month with a Letter of Intent (LOI) that converts
into a firm order unless the LOI is cancelled within one month.

BDAL and Variagenics will coordinate any changes in the delivery schedule. If
delivery occurs more than 30 days beyond the agreed upon delivery date,
Variagenics will receive an additional [__]% discount for each full week that
the system is late up to a maximum discount of [__]% per system.

INSTALLATION, WARRANTY AND SERVICE

BDAL remains responsible for installation, warranty service and post-warranty
service of all autoflex systems.

The purchase of each autoflex system includes one installation and demonstration
of specifications by BDAL free-of-charge. As an option to the Customer, BDAL
will supply one day training for one person specifically for GenoTools software
at an additional cost of $[_______]/proposal to be performed at either the BDAL
Billerica site or at Variagenics, Inc. The cost of consumer site preparation
according to BDAL's site planning guide shown in Attachment B or rigging and
transportation of the system into the Variagenics or customer lab, and
consumables required for the installation, are not included in the BDAL OEM
price. Additional installations, if any, will be billed by BDAL to Variagenics
at normal posted service rates outlined in Attachment C.

Each system price includes a one-year limited warranty under BDAL's standard
warranty terms. The period of the warranty is one year following demonstration
of specifications, but in any event not more than 15 months after delivery. The
warranty covers both parts

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

and labour. For those items supplied by not manufactured by BDAL, the warranty
terms of the manufacturer will be transferred to the buyer.

After expiration of the one-year limited warranty, Variagenics or the final
customer may purchase additional annual Maintenance Service Agreements (MSA) or
per-call service from the BDAL service organization in each country at normal
MSA or per-call service rates, posted in each country from time to time. If the
customer requires additional response time guarantees, or 24/7 coverage, then
surcharges to the normal MSA rates will apply.

JOINT SALES CASES

In selected customer cases, Variagenics and BDAL may jointly pursue the sale of
a larger Variagenics genotyping product offering, including an autoflex system.
However, Variagenics shall receive OEM pricing and volume discounts provided in
this Agreement for any joint sale to Variagenics' customers or partners or any
sale which involves a Variagenics system

CUSTOMER PROTECTION PROCEDURE

Variagenics and BDAL will designate one contact sales manager (Variagenics:
Christopher Hargadon, BDAL: Victor Fursey) to administer the following
agreed-upon customer protection procedure:

When one party forwards a specific serious customer lead in writing (including
e-mail) to the other, this sale becomes an exclusive "Joint Sales Case" for a
period of six months, unless the other party within one week of receipt of the
lead, responds in writing and demonstrates with reasonable written
documentation, that it had previously already vigorously pursued this particular
lead on its own. In this case, an exclusive "Joint Sales Case" means that the
party identifying the customer lead is the main contact for the "Joint Sales
Case".

This lead exchange procedure shall not be abused by either party, and is not
intended for exchanging lists of customers, just in case they someday become
serious prospects. Therefore, at any given time, it is not anticipated, unless
specifically agreed in writing, that the number of protected Joint Sales Cases
exceed 5-10 worldwide at any given time.

As indicated above, Variagenics shall receive the OEM pricing and volume
discounts provided in this Agreement for any sale to Variagenics' customers or
partners or any sale which involves a Variagenics system.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

FUTURE DEVELOPMENTS AND CONFIDENTIALITY

For future development efforts, whether joint, jointly funded, or whether they
simply require the exchange of confidential or proprietary information,
Variagenics and BDAL will conclude a Confidential Disclosure Agreement (CDA),
substantially in the form of Attachment D to protect each party's confidential
and proprietary information, intellectual property, know-how, and trade secrets.
Such a CDA will be structured with an "open annex", which will be updated and
extended by mutual agreement, as disclosures of additional confidential
information occur over the term of this Agreement.

Before disclosing confidential information which is not covered in the CDA
executed in connection with this Agreement, each party will verify whether the
other party wishes to receive such confidential information. Additional topics
to be covered by the CDA and added to its "open annex" have to be clearly
identified, and the purpose for disclosure explained, before thay are added to
the CDA annex by mutual agreement.

Except as may be mutually agreed upon in writing between BDAL and Variagenics as
to publicity parameters, neither BDAL or Variagenics shall use the name of the
other in any advertising, press releases, or other sales communications without
prior written consent of the other party.

LICENSING BDAL'S MALDI-TOF IP FOR BDAL OEM SYSTEMS

With the purchase of each autoflex, Variagenics and its final system's customer
shall receive a fully paid-up, royalty-free, non-exclusive license for each
particular autoflex system to use and resell the particular system, either as
received or bundled with the previous party's own system. BDAL represents and
warrants that it has the right to grant Variagenics the licenses contemplated by
this Agreement, thereby providing Variagenics the freedom to use, bundle with
its own system, and resell the product and to sub-license such rights to
partners and customers who use the product as part of Variagenics' system.
Specifically, this license includes the Indiana University patent portfolio on
SVCF (Space-Velocity Correlation Focusing, by Reilly et. al.), and for BDAL OEM
MALDI-TOF systems purchased by Variagenics or its customers, the royalty cost to
Indiana University will be paid by BDAL. A copy of the license is attached as
Attachment E.

BDAL shall defend, indemnify and hold Variagenics and its customers harmless
from and against all claims, damages, costs (including reasonable attorneys
fees), or judgements against Variagenics in which it is determined or alleged
that the sale or the use of any BDAL product infringes on any patent, copyright,
trademark or any other intellectual property right of any third party.
Variagenics agrees that BDAL, at its sole option shall be relieved of the
foregoing obligations unless Variagenics or its customers (i) notifies BDAL
promptly in writing of such claim, suit or proceeding, (ii) gives BDAL available
information and assistance to settle and/or defend any such claim, suit, or
proceeding (iii) gives BDAL authority over the defense or settlement of such
claim as contemplated above, and (iv) refrains from settling such claim without
BDAL's written consent. If a product (or any part thereof) is, or in the opinion
of BDAL, may become,

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

the subject of any claim, suit or proceeding for infringement of any patent,
copyright, or trademark, or if it is determined that a product (or any part
thereof) is infringing and, as a result, its use is enjoined, then BDAL may, at
its option and expense without prejudice to BDAL's obligations above: (I)
procure for Variagenics the right under such patent, copyright, or trademark to
distribute such product (or such part thereof); or (ii) replace such product (or
part thereof) with other suitable parts; or (iii) suitably modify such product
(or part thereof) to make them non-infringing without modifying their
capability; or (iv) if the use of a product (or part thereof) and refund of the
aggregate payment paid therefor by Variagenics less an amount to account for
actual use by Variagenics customer, as measured over a sixty (60) month life
span.

These infringement clauses shall survive termination or expiration of this
Agreement

RELATIONSHIPS OF THE PARTIES

BDAL and Variagenics are independent contractors. Neither party nor their
respective employees, consultants, contractors, or agents, employees, or joint
venturers of the other, nor do they have any authority to bind the other.

GENERAL TERMS AND CONDITIONS

See Attachment F

In the event of a conflict between the terms of this Agreement and an attachment
or appendix, the terms of this Agreement shall govern

For Variagenics:       /s/ Taylor J. Crouch
                      ----------------------
Name:                 Taylor J. Crouch
                      ----------------------
Title:                President and CEO
                      ----------------------
Date:                 3/29/02
                      ----------------------

For Bruker Daltonics: /s/ John Wronka
                      ----------------------
Name:                 John Wronka
                      ----------------------
Title:                VICE PRESIDENT
                      ----------------------
Date:                 3/27/02
                      ----------------------

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

Attachment A: Formal List Price quotation for Autoflex(R) Linear MALDI-TOF MS

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

BRUKER
DALTONICS(R)                                  QUOTATION
MANNING PARK                                  NO.: MS-VGF-03-27-02
BILLERICA, MA 01821 USA
TEL. (978) 663-3660
FAX. (978) 667-5993

                                               DATE: MARCH 27, 2002

                                               DELIVERY: 3-4 MONTHS ARO
CHRISTOPHER J. HARGADON
VARIAGENICS INC                                SHIP VIA: BEST WAY
60 HAMPSHIRE ST.,
CAMBRIDGE, MA, 02139-1548                      PREPARED BY: VICTOR FURSEY

(CHARGADON@VARIAGENICS.COM)                    SALES REPRESENTATIVE: PAT MALLEY

PHONE: 617 588 2228 - FAX: 617 588 5397        PAGE 1 OF 2

1.   AUTOFLEX(TM) MALDI-TOF MS SYSTEM (# 202840)
     TIME-OF-FLIGHT MASS ANALYZER
     -  122 cm linear TOF analyzer for both positive and negative ions
     -  High sensitivity fast MCP detector system with detector housing
     -  Integrated vacuum system and electronics
     -  Silent operation
     -  Ultra-Stable power supplies for TOF analyzer, detector and ion source
     -  Adjustable height
     -  Small footprint
     -  Industrial hardened horizontal design
     -  Self diagnostics
     -  Remote service package included

     GRIDLESS MALDI SOURCE WITH PULSED ION EXTRACTION (PIE(TM))
     -  Ion source and ion lens system
     -  Automatic vacuum lock for sample introduction with inlet vacuum pump
     -  Long Lifetime N2-LASER including variable power attenuator and UV optics
     -  SCOUT(TM) MTP Microtiter Plate Source / Target with Observation Optics
     -  Large area target (12cm x 8cm) with exact dimensions of microtiter plate
     -  SCOUT MTP Target Kit :(FOR VARIAGENICS = 2X600 MICRON ANCHOR CHIP
        PLATES/HOLDERS)
     -  Precise X-Y positioning (5 micron step increments, 20mm/sec. Speed)
     -  High resolution magnifying observation optics with display on PC monitor
        (see below)
     -  Intuitive GUI for simple mouse controlled X-Y positioning
     -  Horizontal probe inlet for adaptation to robotic lines

     PUMPING SYSTEM INCLUDING VACUUM MEASUREMENT AND CONTROL UNIT
     -  300 l/sec turbomolecular pump including fore-pump
     -  Vacuum measurement system and control unit integrated in GUI
     -  Silent operation

     DATA SYSTEM AND SOFTWARE
     -  2 GHz Digitizer
     -  PC / Windows(TM) NT, > 1 GHz processor, 512 MB RAM, 80 GByte hard disk,
        1.44 MB floppy drive, CD-RW drive, CD-ROM drive, 2 x Ethernet connection
        for external networks and system control, 21" color monitor
     -  Mass spectrometry software FLEX Control NT and XMASS(TM) NT for analysis
        in a networked multi-user environment
     -  AutoXecute with fuzzy-logic optimization for automated acquisition
     -  Laser printer

     SYSTEM LIST PRICE                                          $ [            ]

--------------------------
QUOTATION ONLY VALID WHEN                           BY: /s/ John Wronka
SIGNED BY CORPORATE OFFICER                             ----------------------
                                                        AUTHORIZED SIGNATURE

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

BRUKER
DALTONICS(R)                                  QUOTATION
MANNING PARK                                  NO.: MS-VGF-03-27-02
BILLERICA, MA 01821 USA
TEL. (978) 663-3660
FAX. (978) 667-5993

                                              DATE: MARCH 27, 2002

                                              DELIVERY: 3-4 MONTHS ARO
CHRISTOPHER J. HARGADON
VARIAGENICS INC                               SHIP VIA: BEST WAY
60 HAMPSHIRE ST.,
CAMBRIDGE, MA, 02139-1548                     PREPARED BY: VICTOR FURSEY

(CHARGADON@VARIAGENICS.COM)                   SALES REPRESENTATIVE: PAT MALLEY

PHONE: 617 588 2228 - FAX: 617 588 5397       PAGE 2 OF 2

2.   GENOTOOLS 1.1 (FOR PC-NT SYSTEMS- P/N #74575 & ONE LICENSE #208437) $[    ]

     Software for MALDI-TOF SNP genotyping in combination with genotools, the
     Daltonics MALDI-TOF systems can now be used as reliable, highly automated
     systems for high throughput SNP genotyping. GENOTOOLS 1.1 features the SNP
     MANAGER, which allows for automatic SNP genotyping of samples from 384 well
     targets. Simultaneous SNP genotyping for multiple biallelic markers
     (multiplex analysis) is supported.

     FUNCTIONS OF THE SNP MANAGER:
     -  Administration of sample preparation data
     -  Setup of primer extension reactions for generation of allele-specific
        single stranded DNA fragments
     -  Calculation of molecular masses of extension primer and expected
        products
     -  Definition of critical data processing settings for peak picking and
        calibration
     -  Control of the genotyping analysis by FLEX MS systems
     -  Display of detailed results, including reliability evaluation
     -  Result overview for complete 384 well target plates
     -  Storage of detailed results and summary in table format for export and
        further processing

     Works on NT platform, networking with Daltonics MALDI-TOF data acquisition
     and processing software (FLEX Control NT, XMASS/XTOF 5.1 )

     TRAINING :

3.   FACTORY TOF BASIC TRAINING COURSE, #205891                    $ [         ]
     -  3 days course at the factory
     -  Includes instrument control, data acquisition and processing
     -  Includes sample preparation and application-specific training
     -  Price is per person and excludes all travel & lodging expenses

--------------------------
QUOTATION ONLY VALID WHEN                           BY: /s/ John Wronka
SIGNED BY CORPORATE OFFICER                             ----------------------
                                                        AUTHORIZED SIGNATURE

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

Attachment B: Site Preparation/Facilities information for Autoflex(R) Linear
MALDI-TOF MS

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

AUTOFLEX-TM- -- SITE PREPARATION SPECIFICATION                [BRUKER LOGO]

                                [PHOTO OF EQUIPMENT]

INTRODUCTION

Dear Customer,

As you certainly will understand, it is impossible for us to visit future
installation sites in order to make sure that everything is perfectly
prepared for the installation of your new instrument. So we have to put this
task into our customer's hands. However with this document in hand and some
telephone numbers as a backup, the site preparation for your new autoflex-TM-
should not be a problem.

Please follow the directions given in this manual and make sure, that the
installation site complies with your local laws, regulations, codes and
ordinances with regard to electrical and mechanical installations, building
safety and use of hazardous materials/chemicals.

In order to schedule the installation as flexible as possible, please use the
enclosed form in the appendix of this document for your fax reply to the
BRUKER Daltonics Service Team. This fax does also confirm the preparation of
the installation site.
Note, that it is not possible for us to schedule your installation prior to
the receipt of your reply fax.

If there are any questions related to the site preparation for your new
autoflex-TM-, please do not hesitate to contact us by phone or e-mail.

In appreciation of your cooperation,

Your BRUKER Daltonics Service Team

COPYRIGHT(C) DECEMBER 2001
BRUKER DALTONIK GMBH                                          VERSION 1.3

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

READ THESE INSTRUCTIONS BELOW BEFORE ALL CONTINUOS ACTIONS:

PURPOSE OF PROCEDURE
To ensure that the installation site is properly evaluated and prepared with
the appropriate utilities, consumables and supplies for the successful
installation of the autoflex-TM- system. Installation sites should be
prepared in accordance with the following specifications.

IMPORTANT INFORMATION
If you have problems in providing any of the following, please contact your
local BRUKER office for assistance.
Assistance with user specific applications may be provided but should be
contracted separately. Users of the instrument should be present throughout
the installation and the familiarization otherwise important operational,
maintenance and safety information will be missed.

RESPONSIBILITIES OF THE LOCAL BRUKER OFFICE
The local BRUKER office will contact you to determine the required quantity
of low power cords with the appropriate national plug for your country and
site. Please look up the appendix for more details.

PROCEDURE CHECKLIST

RECEIVING THE INSTRUMENT

Examine the shipping container for any obvious external damage after the
receipt.
In the case of an visible damage, make a note on the freight bill: VISIBLE
DAMAGE--SUBJECT TO INSPECTION AND TEST.
Compare the serial numbers of the shock watches with the ones in the delivery
note and record all deviations on the freight bill.
Up to begin of the installation the shipping container should be stored in a
closed storeroom-do not leave them outside.

Do not open the shipping container unless a BRUKER representative is
present--opening of the container without authorized persons will void the
receiving warranty of the instrument--as part of the complete installation
our service engineers will set up the instrument in customers laboratory.

Please note that the delivery of your new instrument will be carried out to
the loading ramp of your building. Transportation tools like pallet jack,
crowbar and electric drill with two rotational directions should be available
to open the shipping containers and maneuver the system to the final place.
Note, that the system is to heavy for a single person. Make yourself sure
about the accessibility of the appropriate areas: All doors, staircases,
floors and elevators must be suitable to the weight and size of the shipping
container or rather instrument. After installation of the instrument the
shipping container pass into customer hands and should not be returned.

AUTOFLEX-TM- SYSTEM MAINFRAME

DIMENSIONS, WEIGHT AND SPACE

LOCATING THE AUTOFLEX-TM- INSTRUMENT

     750 mm x 1920 to 2440 mm(1) x 825 mm
     29.5 in x 75.6 to 96.0 in(1) x 32.5 in
     340 kg/750 lb net weight

LOCATING THE PACKAGINGS

INSTRUMENT:       2050 mm x 840 mm x 1120 mm
                  80.7 in x 33.1 in x 44.1 in
                  477 kg / 1051 lb gross weight

ACCESSORY:        1570 mm x 800 mm x 1310 mm
with Twister-TM-  61.8 in x 31.5 in x 51.6 in
                  220 kg / 485 lb gross weight

ACCESSORY:        820 mm x 760 mm x 1440 mm
without           32.3 in x 29.9 in x 56.7 in
Twister-TM-       165 kg / 363 lb gross weight

(1)  In the case of use of the Twister-TM- microplate handler the height is
fixed to 2045 mm (80.5 in).

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

       LOCATING THE TWISTER-TM- MICROPLATE HANDLER (OPTION)

       DIMENSIONS, WEIGHT AND SPACE

             750 mm x 895 mm x 470 mm
             29.5 in x 35.2 in x 18.5 in
             20 kg / 44 lb net weight

The installation site for the autoflex-TM- must provide sufficient space for
optional equipment, Personal Computer, monitor, printer and other accessories.
Data system size and weight depends on the components included in the data
system. Reserve at least 1000 mm (39 in) of bench space. Typical weights are
40 kg (88 lb) for the data system including a 21"-monitor.

In addition, there must be sufficient space around the system for ventilation
and maintenance access - at least 1000 mm (39 in) to the left, right and front
side and at least 50 mm (12 in) behind the autoflex-TM- must kept clear.

       PICTURE 1:  FLOOR PLAN OF AUTOFLEX-TM- SYSTEM (TOP VIEW)
                   WITH OPTIONAL TWISTER-TM-

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

ENVIRONMENTAL CONDITION REQUIREMENTS

Environmental conditioning considerations include temperature, humidity,
airborne dust and exhaust venting.

The autoflex-TM- is specified for operation under following conditions:

   -  Operating Temperature:  10 to 30 degrees C (50 to 86 degrees F)
   -  Operating Humidity:     15% to 85% non-condensing at 30 degrees C

Note that the guaranteed analytical specifications will be met only within
the temperature range of 21 degrees C plus or minus 3 degrees C (70 degrees F
plus or minus 6 degrees F). Regardless the existing room temperature the
temperature variations shall be less than 3 degrees C/hr.

The autoflex-TM- dissipates up to 2000 Watts (6830 BTU/hr). The data system
and additional equipment also contribute significantly to the cooling load
although the exact amount depend on the configuration.

ELECTRICAL AND POWER SPECIFICATION

The customer is responsible for providing appropriate electrical power and
power outlets for all system components.

The autoflex-TM- instrument is equipped with a wide-range input of 208 VAC to
230 VAC, 50/60 Hz input, which is content with the provided mains supplies
worldwide.
Because of poor mains reliability in local areas customers shall use a
optional available UPS. Customers also can take advantage of the available
UPS to achieve a much lower failure density in automatic, long-drawn-out
measurements, who might be interfered by voltage dips and interruptions.

The terminal connection of the power socket is customers responsibility in
general. The autoflex-TM- has to be powered either with:

   -  208 VAC, plus or minus 10% (dual phase voltage) in North America or
   -  230 VAC, plus or minus 10% or 240 VAC, plus or minus 6% (single phase
      voltage) in European countries respectively Australia.

Customers who take advantage of the UPS must make a hardwire terminal
(junction box) available to connect the autoflex-TM- via the UPS with
stripped conductors. For all other customers a IEC 60309 connector is needed
(Picture 2):

IEC 60309
High Power Connector
16/20A
3 pin, single phase
Wall mounted receptacle

PICTURE 2

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

The current cut-out device should not have a protection less than 10 ampere
for each existing phase:

Note that the correct grounding of the electrical installation must be
guaranteed by the customer:
It is inadmissible to use the neutral wire as safety ground. The ground wire
should be an isolated ground, carrying zero current except in the case of a
fault.
Interruption of the protective conductor can cause a shock hazard for the
user and can damage the instrument.

The other low power equipment like Twister-TM- microplate handler and data
system (computer, monitor, printer) include full-range power supplies, or a
voltage selector in few cases.
You will need a minimum of 4 or more low power cables with your national,
power appropriated and grounded plug and IEC 60320 C19 connector (Picture 3)
on the equipment side.

The local BRUKER office will contact you to determine the required quantity
of power cords appropriate to your site.

Type C19
IEC 60320/C19
max. 16A

                                    PICTURE 3

ADDITIONAL CONSIDERATIONS

-  Plan extra power capacity on your site for additional equipment.
-  Take advantage of an optional Uninterruptable Power Supply (UPS), if your
   mains voltage is unstable or a data protection is needed.
-  If a UPS is not used, each single equipment (autoflex-TM-, data system
   etc.) shall have a own separate circuit with a particular breaker to ensure
   a self-contained run in the case of individual instrument malfunction.
-  It is recommended to install an emergency-off switch stop to interrupt the
   electric circuits and other systems in a emergency case or for maintenance.
-  Electromagnetic interferences, like NMRs, cellular phones and radio
   transmitters may have a bad effect on system performance.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

LABORATORY GAS SUPPLY REQUIREMENTS

NITROGEN GAS REQUIREMENTS

The specified performance of the autoflex-TM- contingent on a constant supply
of nitrogen for the operation and ventilation of the laser system.

The average nitrogen flow rate of the laser come to 5 1/hr at a maximum of
2.5 bar (36 PSI).
You can calculate the usable amount of nitrogen (liter), if you multiply
bottle volume (liter) and filling pressure (bar).

We recommend a high pressure nitrogen cylinder configuration with a minimum
demand of 1 cylinder.

NITROGEN PURITY

The nitrogen gas must be free of contaminants in dependence on the source of
the nitrogen. Reason for this are the different types of contaminants usual to
the different nitrogen sources:

Bottled nitrogen for example have a tendency to be contaminated with
hydrocarbons, which can be the reason for a widely deviation to BRUKER's
specified performance and a damaging of the laser.
Therefore we highly recommend gas quality 4.6 (99.996% purity) or better,
otherwise the laser head will be damaged irreversible.
Note:  Even an optional available gas purifier can be unable to remove all of
       the hydrocarbon contaminants.

ADDITIONAL CONSIDERATIONS

To satisfy the prior preparation of the site before installation date, the
customer must ensure the following (user) connections of gas supply:

  -  Nitrogen:  SWAGELOK male connection, metric thread, for BRUKER's 6 mm
                Teflon tube,
                [5 m tube (16 ft), 6 mm diameter, 1 mm wall thickness,
                will be supplied with instrument].

Ensure that an appropriate pressure control regulator is available - the
regulator must be able to supply gas according to the bottle pressure on
high-pressure side up to 300 bar in general and typically 0.5 to 4 bar (7 to
58 PSI) absolute value on low-pressure side. Be sure you select a super-clean
regulator.

If you are equipped with nitrogen from a house installation the regulator can
usually be a single-stage one, if the supply pressure is higher than the
above specified one. In comparison a high pressure nitrogen cylinder
configuration requires a dual-stage regulator.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

EXHAUST VENTING REQUIREMENTS

Exhaust venting is required for user safety. Health hazards include chemical
toxicity of samples as well as pump fluid vapor e.g. and must be vented
externally to the building and not recirculated by the environmental control
system.

Connection to ventilation system shall be direct to building exterior or to
clean fume hood to prevent possible bay flow of contaminants - loss of
nitrogen gas may occur due to this.

     PUMP EXHAUST

     Location:          Pump outlet of the mist filter at the
                        back of the autoflex-TM- instrument
     Suggested tubing
       to exhaust:      13 mm (1/2") diameter plastic tubing (Tygon)
     Capacity:          1 to 2 1/h

The exhaust (environmental) system must be designed and controlled as
directed in conformance with all local laws (codes, ordinances and
regulations).

Dangerously high pressure can be build up in the exhaust pipe--never use a
stop valve on the exhaust side. If a blocking unit is installed because of
internal company reasons, or in the risk of a overpressure in the exhaust
pipe all official accidental regulations have to be observed.
Exhaust pipings should be installed in a falling horizontal direction, so
that no condensate can run back to the pump-otherwise install separators.

For additional descriptions and special maintenance instructions regarding
this subject we recommend the manufacturer manuals.

Furthermore a enclosed 100 mm (3.93 in) diameter flexible tubing can be
installed to vent the cooling air to the outside of the room.

SAFETY PRECAUTIONS

The standard Nitrogen laser emits high intensity radiation at 337 nm, 150
micro Joules max. (Class IIIb laser classification). Laser radiation is
invisible to the eye cause damage to it.

To safeguard the user both side doors of autoflex-TM- instrument are equipped
with locks which prevent users from the laser - during normal operation mode
with all covers closed (i.e. Class I laser classification) no laser radiation
can be transmitted outside the spectrometer.
BRUKER strongly does not recommend bypassing or disabling any of the safety
features of autoflex-TM- instrument by anyone other than trained BRUKER
service engineers or running the system without covers - BRUKER will not take
over any responsibility in such cases.

The spectrometer operation involves use of high voltages. The access of high
voltage cables and high voltage feedthroughs is restricted behind the side
doors of the instrument as far as possible. Accessible high voltage
connections are marked with danger signs according to regulations.

BRUKER will not take over any responsibility for any injury incurred as
result of a misappropriate use of the instrument.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

TECHNICAL ASSISTANCE

If you need any assistance please call or write to

     BRUKER Daltonik GmbH
     Fahrenheitstrasse 4
     28359 Bremen
     Germany

     Phone    : ++49-(0)421-2205-200   Sales Department
                ++49-(0)421-2205-430   Service Department

     Fax      : ++49-(0)421-2205-103   Sales Department
                ++49-(0)421-2205-106   Service Department

     E-mail   : sales@bdal.de
                autoflex_service@bdal.de

     Internet : www.bruker-daltonik.de

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

APPENDIX

FAX REPLY TO BRUKER DALTONICS SERVICE DEPARTMENT:

Dear customer,

for the correct and fast installation of the new autoflex-TM- at your site we
need your confirmation of the realized site preparation in conformance with
the handed over Site Preparation Specification document. Moreover we need your
informations to configure the computers for your network.

Ensure that the fax reply will be returned at least 4 weeks before instrument
installation-the BRUKER Daltonics Service Team is not able to begin
installation without customers confirmation!

------------------------------------------------------------

Hereby I/we verify that all of the below mentioned site preparations criteria
have been fulfilled:

                   / /  Suitable space for the instrument
                   / /  Electrical installation according to Site Preparation
                        Specification and common electrical rules
                   / /  Exhaust ventilating outlet
                   / /  Network Setup according to BRUKER MALDI-TOF Computer
                        Configuration List

     ------------------------------
     Company/Institute

     ------------------------------               ------------------------------
     Address                                      Postal Code, City

     ------------------------------               ------------------------------
     Name                                         Job Position

     ------------------------------               ------------------------------
     Telephone                                    Fax

     ------------------------------
     E-mail

     ------------------------------               ------------------------------
     City, Date                                   Signature/Stamp

     PLEASE SEND THE STATEMENT TO:

                                                  ------------------------------

                                                              STAMP

                                                  ------------------------------

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

                       FAX REPLY TO BRUKER - Page 1 of 2

<Page>

BRUKER MALDI - TOF COMPUTER CONFIGURATION LIST

       CUSTOMER DATA

              ADDRESS:
                       ---------------------------------------

                       ---------------------------------------

                       ---------------------------------------

                       ---------------------------------------

              CONTACT PERSON:                   SYSTEM ADMINISTRATOR:

                       Mr./Mrs.                 Mr./Mrs.
                       ----------------------  -------------------------------
              TELEPHONE:
                       ----------------------  -------------------------------
              FAX:
                       ----------------------  -------------------------------
              E-MAIL:
                       ----------------------  -------------------------------

              PLEASE NOTE, THAT THE STANDARD LENGTH OF NETWORK CONNECTION
              CABLES DELIVERED BY BRUKER IS LIMITED TO 10 METERS. LONGER
              CABLES MUST BE ORDERED SEPARATELY!

       TECHNICAL DATA
       (use as often as the number of computers)

              / / PC UNIT(S) (please fill out for each PC)

                  HOSTNAME (E.G. TOF-MS)
                  (if left blank, chosen by Bruker)
                                                   ---------------------------

                  IP ADDRESS (E.G. 192.168.200.1)
                  (if left blank a non-internet-routeable
                  address is chosen)
                                                   ---------------------------

                  SUBNETMASK (E.G. 255.255.255.224)
                  (if left blank, no subnetting is assumed)
                                                   ---------------------------
                  DEFAULT GATEWAY (IP ADDRESS)
                  (if left blank, no default router is assumed)
                                                   ---------------------------
                  DNS IP ADDRESS (IP ADDRESS)
                  (if left blank, no domain server is assumed)
                                                   ---------------------------
                  DNS DOMAIN NAME (E.G. BRUKER.COM)
                  (if left blank, no domain name is assumed)
                                                   ---------------------------

       IF YOU ARE RUNNING A LAN AND/OR IF YOU WANT TO CONNECT MORE THAN ONE PC,
       PLEASE ANSWER THE NEXT TWO QUESTIONS:

              IS THERE A HUB FOR CONNECTING YOUR NEW COMPUTER TO YOUR LAN?

                / / YES     or     / / NO

              IF BRUKER SHOULD PROVIDE A HUB, WHAT IS YOUR LAN'S BANDWIDTH?

                / / 10 MBit  or    / / 100 MBit

              IS THERE SOMETHING ELSE YOU WANT TO BE CONSIDERED FOR THE
              NETWORK SETUP OF YOUR NEW COMPUTERS?

              ----------------------------------------------------------------

              ----------------------------------------------------------------

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

                         FAX REPLY TO BRUKER - PAGE 2 OF 2
<Page>

Attachment C: Chart of Service and Travel Charges.

<Table>
<S>                                                                <C>
1. Service Labor Rate for on-site service call                     $ 1600.00 per day
2. Additional Half-Day on site service (without overnight stay)    $  850.00 per 1/2 day
3. In house repairs (Price per hour, minimum 1 hour)               $  175.00 per hour
</Table>

Zone Charge (applied for the first day of on-site service):

<Table>
<Caption>
Region :     Mileage from BDAL:          Zone Charge:
<S>          <C>                         <C>
#1           0-100 miles                 $  400.00
#2           101-300 miles               $  950.00
#3           301-750 miles               $ 1400.00
#4           751-1000 miles              $ 1750.00
#5           1001 plus miles             $ 2131.50
</Table>

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

Attachment D: Confidential Disclosure Agreement

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

                             BRUKER DALTONICS, INC.
             Standard Confidential Information Disclosure Agreement

EFFECTIVE DATE:  January 1st 2002

In order to protect certain confidential information Bruker Daltonics and its
corporate affiliates ("Bruker"), and the "Participant" identified below, agree
that:

1.   PARTIES TO THE AGREEMENT: The parties to this Agreement, and their
     addresses, are:

     Bruker Daltonics Inc.                          Variagenics, Inc.
     Manning Park                                   60 Hampshire Street
     Billerica, MA 01821                            Cambridge, MA 02139

            "Bruker"                           "Participant"

2.   PRIMARY REPRESENTATIVES: The parties appoint the following representatives
     to disclose and receive Confidential Information:

     For Bruker:                                    For Participant:

     John Wronka Ph.D.                              Taylor J. Crouch

3.   DESCRIPTION OF CONFIDENTIAL INFORMATION: The Confidential Information to be
     disclosed under the terms of this Agreement is described as:

     a. Confidential Varigenics developments on Modified Nucleotides

     b. Confidential Variagenics information on utilizing modified nucleotides
        in genotyping, haplotyping, or variance discovery.

     c. Confidential Bruker Mass Spectrometry developments

     d. Confidential information on Bruker's and Variagenics business strategy
        and plans, and R&D plans

4.   USE OF CONFIDENTIAL INFORMATION: Subject to the exceptions stated below, a
     recipient of Confidential Information shall not disclose the Confidential
     Information or use the Confidential Information except for the purpose of
     this Agreement which is:

     The collaboration agreement between Variagenics and Bruker Daltonics
     referenced in the renewed Collaboration agreement for 2002.Recipient shall
     not use Confidential Information for it's own benefit or the benefit of
     another without Discloser's consent.

5.   CONFIDENTIALITY PERIOD: This Agreement and Recipient's duty to hold
     confidential information and intellectual property rights under this
     Agreement in confidence expire on:

     5 years after disclosure of each item

6.   DISCLOSURE PERIOD: This Agreement pertains to confidential information that
     is disclosed between the Effective Date and 31st March 2003

7.   STANDARD OF CARE: Recipient shall protect the disclosed confidential
     information by using the same degree of care, but no less than a reasonable
     degree of care, to prevent the unauthorized use, dissemination, or
     publication of the confidential information as Recipient uses to protect
     its own confidential information of a like nature.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

                                                                          Page 1
<Page>

8.   MARKING: Recipient's obligations shall only extend to confidential
     information that is described in paragraph 3, and that: (a) comprises
     specific materials individually listed in paragraph 3; or, (b) is marked as
     confidential at the time of disclosure; or, (c) is unmarked (e.g. orally
     disclosed) but treated as confidential at the time of disclosure, and is
     designated as confidential in a written memorandum sent to Recipient's
     primary representative within thirty days of disclosure, summarizing the
     confidential information sufficiently for identification.

9.   EXCLUSIONS: This Agreement imposes no obligation upon Recipient with
     respect to information that: (a) was in Recipient's possession before
     receipt from Disclose; (b) is or becomes a matter of public knowledge
     through no fault of Recipient; (c) is rightfully received by Recipient from
     a third party without a duty of confidentiality (d) is independently
     developed by Recipient without reference to or reliance upon the
     Confidential Information (e) is required to be disclosed under operation of
     law provided Recipient provides discloser with prior written notice of
     intended disclosure; or (f) is disclosed by Recipient with Disclosure's
     prior written approval.

10.  WARRANTY: Each Disclosure warrants that it has the right to make the
     disclosures under this Agreement. NO OTHER WARRANTIES ARE MADE BY EITHER
     PARTY UNDER THIS AGREEMENT, ANY INFORMATION EXCHANGED UNDER THIS AGREEMENT
     IS PROVIDED "AS IS".

11.  RIGHTS: Neither party acquires any intellectual property rights under this
     Agreement. This agreement shall not restrict reassignment of Recipient's
     employees, provided that such employees remain bound by the provisions of
     this agreement.

12.  This Agreement imposes no obligation on either party to purchase, sell,
     license, transfer or otherwise dispose of any technology, services or
     products.

13.  Both parties shall adhere to all applicable laws, regulations and rules
     relating to the export of technical data, and shall not export or re-export
     any technical data, any products received from Disclosure, or the direct
     product of such technical data to any proscribed country listed in such
     applicable laws, regulations and rules unless properly authorized.

14.  This Agreement does not create any agency or partnership relationship.

15.  All additions or modifications to this Agreement must be made in writing
     and must be signed by both parties.

16.  This Agreement is made under, and shall be construed according to, the laws
     of the Commonwealth of Massachusetts.

By the signatures below of their authorized representatives, Bruker and
Participant acknowledge that they have read, understood and accepted all of the
terms and conditions of this Agreement.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

                                                                          Page 2
<Page>

BRUKER DALTONICS INC.                       VARIAGENICS, INC. (PARTICIPANT)

Name:      John Wronka                      Name:      Taylor J. Crouch
           ---------------------                       -------------------------
Title:     Vice-President                   Title:     President & CEO
           ---------------------                       -------------------------
Signature: /s/ John Wronka                  Signature: /s/ Taylor J. Crouch
           ---------------------                       -------------------------
Date:      March 27, 2002                   Date:      March 29, 2002
           ---------------------                       -------------------------

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

                                                                          Page 3

<Page>

Attachment E: Space-Velocity Correlation Focussing License

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

                            OEM SUB-LICENSE AGREEMENT

     THIS AGREEMENT (the "Agreement") is made and/or entered into by and between
Bruker Daltonics Inc. ("Licensor"), a Delaware corporation with its principal
place of business at Fortune Drive, Manning Park, Billerica, Massachusetts
01821, and Variagenics, Inc. ("Licensee"), a Delaware corporation with its
principal place of business at 60 Hampshire Street, Cambridge, MA 02139.

     WHEREAS, Licensor is the exclusive licensee of, having the full right to
grant sublicenses to, the Patent Rights, as these are defined with particularity
herein; and

     WHEREAS, Licensee desires to obtain a license under certain patent rights
held by Licensor, as defined with particularity in this Agreement;

     NOW, THEREFORE in view of the promises set forth below, the parties hereto
agree as follows:

1.   DEFINITIONS

     Solely for the purposes of this Agreement the following terms, as used
     herein, will have the meanings specified below:

          1.1  "Effective Date" means the date last written below.

          1.2  "Patent Rights" means those patents and/or patent applications
          listed on Schedule A and any patents issuing from such patent
          applications, or any related U.S. or foreign applications or patents
          based upon any of such patent applications or patents, as well as any
          continuations, divisions, reexaminations, reissues, substitutes,
          renewals or extensions of any of the foregoing patent applications or
          patents.

          1.3  "Affiliate" of a specified entity means an entity that directly
          or indirectly controls, is controlled by, or is under common control
          with, the specified entity. For purposes of this Agreement, the direct
          or indirect ownership of more than 50% of the outstanding voting
          shares of an entity, the right to receive 50% or more of the profits
          or earnings of an entity, or the right to control policy decisions of
          an entity, will be deemed to constitute control.

          1.4  "Licensed Product" or "Licensed Products" means and includes any
               apparatus, device, system, product, article of manufacture,
               appliance, method or process, the practice, manufacture, use or
               sale of which would be, but for this Agreement, covered in whole
               or in part by a pending claim in a pending application within the
               Patent Rights or an unexpired claim in a patent within the Patent
               Rights.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

2.   GRANT OF SPECIAL OEM SUB-LICENSE

          2.1. Licensor hereby grants an individual systems' license to
               Licensee, with the right to grant sublicenses to its Affiliates,
               to use and/or to re-sell each MALDI-TOF mass spectrometer
               purchased by Licensee from Licensor under a separate
               "COLLABORATION AGREEMENT", dated May 24, 2000, and to grant its
               customers an individual systems' license to use for each
               MALDI-TOF mass spectrometer purchased under the "COLLABORATION
               AGREEMENT" .

          2.2. Pursuant to the separate "COLLABORATION AGREEMENT" Licensor shall
               be responsible for the payment of all royalties to IU-ARTI on
               Licensor's MALDI-TOF systems sold as OEM systems to Licensee.

          2.3. Any license granted under this Agreement shall not constitute or
               be interpreted as a license to the Licensee for manufacture, use
               or sale of any other MALDI-TOF or other mass spectrometer, other
               than the OEM MALDI-TOF systems specifically purchased from
               Licensor under the terms of the "COLLABORATION AGREEMENT". In
               particular, this Agreement does not waive for the Licensee future
               access payments, retroactive or future royalty payments on any
               other MALDI-TOF or other mass spectrometer not specifically
               covered by this Agreement.

3.   PAYMENTS/LICENSE FEES AND ROYALTIES

This section is not applicable, as Licensor pays all royalties to IU-ARTI for
OEM MALDI-TOF systems sold to Licensee under the separate "COLLABORATION
AGREEMENT".

4.   REPRESENTATION AND WARRANTIES

     Licensor warrants that, to the best of its knowledge and belief, it is the
     sole exclusive licensee of all rights, title, and interest in the Patent
     Rights, free of any liens, encumbrances, restrictions and other legal or
     equitable claims, subject, however, to any rights of governmental
     authorities, including full right and authority to sublicense the Patent
     Rights.

5.   RECORDS, REPORTS, AND PAYMENTS

          5.1  not applicable

          5.2  not applicable

          5.3  not applicable

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

          5.4  not applicable

6.   TERM OF THE AGREEMENT

          6.1  Unless sooner canceled or terminated as herein provided, the
          individual system's license granted under this Agreement will continue
          (10) years or for the full term of the last expiring patent or patent
          application within the Patent Rights, whichever is longer.

          6.2  If Licensee becomes bankrupt or insolvent, or files a petition in
          bankruptcy, or if the business of Licensee is placed in the hands of a
          receiver, assignee or trustee for the benefit of creditors, whether by
          the voluntary act of Licensee or otherwise, this Agreement will
          automatically terminate without any notice whatsoever to Licensee.

          6.3  not applicable

          6.4 Licensee will have the right to terminate this Agreement with or
          without cause at any time upon six (6) months written notice to
          Licensor.

          6.5  not applicable

          6.6  If, at any time during this Agreement, Licensee directly or
          indirectly opposes or assists any third party to oppose the grant of
          any Letters Patent on any patent application within the Patent Rights
          or disputes or directly or indirectly assists any third party to
          dispute the validity of any patent within the Patent Rights, or any of
          the claims thereof, Licensor will be entitled thereafter to terminate
          immediately all or any portion of the license granted under this
          Agreement by notice thereof to Licensee.

          6.7  In the event that any claim of any application within the Patent
          Rights is canceled, abandoned, or otherwise disallowed by a final
          non-appealable or non-appealed action of a Patent Office having
          jurisdiction, or in the event that any claim of any patent within the
          Patent Rights is held invalid or unenforceable by a non-appealable or
          non-appealed decision by any court of competent jurisdiction, such
          claim will be deemed to have expired, as of the date of final
          disallowance or final decision of invalidity or non-enforceability.

          6.8  Provisions of this Agreement which by their nature contemplate
          rights and obligations of the parties to be enjoyed or performed after
          the expiration or termination of this Agreement will survive until
          their purposes are fulfilled. Termination of this Agreement for any
          reason

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

          will not relieve either party of its obligations under this Agreement
          previous to the effective date of such termination.

7.   NON-TRANSFERABILITY OF LICENSES

          7.1  The license granted by this Agreement can be transferred by the
          Licensee, but only as part of a transaction by which the Licensee
          divests itself of all or substantially all of the business of
          manufacturing and/or selling Licensed Products. In the event of such a
          transfer, Licensee and its Affiliates shall thereupon cease to be
          Licensees hereunder.

          7.2  Should any entity or person cease to be an Affiliate of a party,
          as that term is defined in paragraph 1.3 above, this Agreement shall
          be terminated as to that entity or person, who shall have no further
          rights or obligations under this Agreement.

          7.3  The license granted in this Agreement shall be binding upon any
          successor of Licensor in ownership or control of the Patent Rights,
          and the obligations of Licensee shall run in favor of any such
          successor of Licensor's benefits under this Agreement.

8.   PAYMENTS, NOTICES AND OTHER COMMUNICATIONS

     Any payment, notice, or other communication pursuant to this Agreement will
     be sufficiently made or given on the date of mailing if sent to such party
     by express mail or certified first class mail, postage prepaid, made out to
     Bruker Daltonics, Inc. and addressed to it at its address below or made out
     to Licensee and addressed to it at its address below as either party will
     designate by written notice given to the other party:

     Licensor:      Frank H. Laukien, President
                    Bruker Daltonics Inc.
                    Fortune Drive, Manning Park
                    Billerica, MA  01821

     Licensee:      Taylor Crouch, President
                    Variagenics, Inc.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

                    60 Hampshire Street
                    Cambridge, MA 02139

9.  MISCELLANEOUS PROVISIONS

          9.1  Each party hereto agrees that it will not release any information
          to any third party with respect to the Terms of this Agreement without
          the prior written consent of the other party. This prohibition
          includes, but is not limited to, press releases, educational and
          scientific conferences,
          promotional materials and discussions with lenders, investment
          bankers,
          public officials and the media. Should any third party seek to obtain
          any
          information by legal process with respect to the existence or terms of
          this Agreement from either party hereto or if disclosures related to
          this
          Agreement are required by law, such Party shall promptly notify the
          other Party hereto, and shall take all appropriate measures to avoid
          and minimize the release of such information

          9.2  This Agreement will be construed, governed, interpreted, and
          applied in accordance with the laws of the Commonwealth of
          Massachusetts, U.S.A., except that questions affecting the
          construction and effect of any patent will be determined by the law of
          the country in which the patent was granted.

          9.3  not applicable

          9.4  This Agreement constitutes the entire understanding between the
          Parties hereto with respect to the subject matter hereof other than
          the "COLLABORATION AGREEMENT". This Agreement supersedes any prior
          agreements between the Parties hereto as to the subject matter of this
          Agreement except as specifically provided herein. No modification,
          extension or waiver of any provision hereof or any release of any
          right hereunder shall be valid, unless the same is in writing and is
          consented to by both Parties hereto.

          9.5  The provisions of this Agreement are severable, and if any
          provision of this Agreement is held to be ineffective, unenforceable
          or illegal for any reason, such ineffectiveness, unenforceability
          and/or illegality shall not affect the validity or enforceability of
          any or all of the remaining portions hereof.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

          9.6  This Agreement shall be construed in accordance with its fair
          meaning and not strictly for or against any Party.

          9.7  This Agreement may be executed simultaneously in two or more
          counterparts, each of which shall be deemed an original, but both of
          which together constitute one and the same Agreement.

          9.8  Paragraph titles or captions contained herein are inserted only
          as a matter of convenience and for reference, and in no way define,
          limit, extend, or describe the scope of this Agreement, nor the intent
          of any provision thereof.

          9.9  Each Party acknowledges that it has or has, had the opportunity
          to consult with counsel of its choice and that in executing this
          Agreement it has not relied upon any statements, representations or
          agreements of any other person other than those contained herein.

          9.10 not applicable

          9.11 not applicable

          9.12 No failure or delay on the part of either Party hereto in the
          exercise of any power, right or privilege under this Agreement shall
          operate as a waiver thereof, nor shall any single or partial exercise
          of any such power, right or privilege preclude other or further
          exercise thereof or of any other right, power or privilege.

          9.13 Nothing in this Agreement shall be construed as:

               (a)  a warranty or representation as to the validity,
               enforceability or scope of any patent by the Licensor;

               (b)  a warranty or representation that any manufacture, sale,
               lease, use or importation will be free from infringement of
               patents other than those under which and to the extent to which
               licenses or covenants are in force hereunder, including patents
               of third parties;

               (c)  an agreement to bring or prosecute actions or suits against
               third parties for infringement;

               (d)  conferring any right to use, in advertising, publicity or
               otherwise, any name, trade name, trademark, service mark, symbol
               or any other identification or any contraction, abbreviation or
               simulation thereof,

               (e)  conferring by implication, estoppel or otherwise any license
               or other right under any patent, except as expressly granted
               herein;

               (f)  a representation or warranty of any kind or the assumption
               of any responsibility whatsoever by any Party with respect to the
               manufacture, sale, lease, use or other disposition

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

               of any product or method licensed hereunder (including without
               limitation, claims of third parties asserting that a product is
               defective or unsafe for its intended purpose); and

               (g) a representation deemed to place Licensee and Licensor in a
               partnership, joint venture or agency relationship and neither
               party will have the right or authority to obligate or bind the
               other party in any manner.

          9.14 All notices and communications provided for hereunder shall be in
          writing and shall be mailed or delivered to the business address of
          the respective Parties as aforementioned, or to such other address as
          any Party may designate from time to time in writing to the other.

          9.15 Each of the Parties agrees to perform reasonably requested
          actions of the other Party which are required to effectuate the
          covenants and purposes of this Agreement.

     IN WITNESS WHEREOF, the parties hereto have hereunto set their hands and
seals and duly executed this Agreement as of the day and year set forth below.

    LICENSEE                                  LICENSOR

BY: /s/ Taylor J. Crouch                       BY: /s/ John Wronka
    -----------------------------                  -----------------------------
    Taylor Crouch                                  John Wronka
    President & CEO                                Vice-President
    Variagenics Inc.                               Bruker Daltonics Inc.

DATE: March 29, 2002                               DATE: March 27th 2002

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

                                   SCHEDULE A

<Table>
<Caption>
  US PAT. NO.     INVENTOR(S)            TITLE
  -----------     -----------            -----
<S>               <C>                    <C>
  5,504,326       James P. Reilly        Spatial-Velocity Correlation Focusing
                  Steven M. Colby        in Time-of-Flight Mass Spectrometry
                  Timothy B. King

  5,510,613       James P. Reilly        Spatial-Velocity Correlation Focusing
                  Steven M. Colby        in Time-of-Flight Mass Spectrometry
                  Timothy B. King

  5,712,479       James P. Reilly        Spatial-Velocity Correlation Focusing
                  Steven M. Colby        in Time-of-Flight Mass Spectrometry
                  Timothy B. King
</Table>

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

Attachment F: General Terms and Conditions

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

                                  WARRANTY

All standard products sold by Bruker Daltonics, Inc. (hereinafter called
"DALTONICS") carry a limited warranty, subject to the terms and conditions
hereby set forth. The product is warranteed for one year to be free of
defects in material and workmanship. DALTONICS obligation under all
warranties is limited in accordance with the periods of time and all other
conditions stated in all provisions of the warranty, including the periods
and conditions provided in the special warranty statements applicable to
Special Products Custom Products and Accessories.

                              WARRANTY PERIOD

The applicable warranty period shall begin upon demonstration of
specifications. The warranty for accessories (other than complete
spectrometers) shall commence upon shipment from DALTONICS. Short shipment of
individual times does not delay commencement of the warranty period. Upon
beginning of the applicable DALTONICS warranty period, all Customer remedies
shall be governed by the provisions stated in the warranty. In no event
shall such warranty period extend more than fifteen (15) months from the date
of shipment of the Product.

                             WARRANTY COVERAGE

The warranty coverage is subject to all the following limitation:

1. This warranty applies only to defects in material and workmanship in
covered Products and is not to be interpreted as providing full service
coverage for such items as routine maintenance, adjustments, or recalibration
as defined by the instruction manual.
2. This warranty covers only parts and labor furnished by DALTONICS. This
warranty does not cover products or services provided by an outside
manufacturer, which may be repaired or replaced according to the original
manufacturer's warranty terms, if any. DALTONICS accepts no responsibility
for failure of the original manufacturer to perform under its own warranty
obligations.
3. The following are expressly not covered under warranty:
a). Any loss, damage, and/or instrument malfunction relating in any way to:
       - Shipping or storage;
       - Accident, abuse, alteration, misuse, or neglect;
       - Breakage or abuse of parts;
       - Operation other than in accordance with correct operating procedures;
       - Tampering with the system (e.g., modification or tampering with one
         part of the instrument can, in some cases, affect another part of the
         instrument)
       - Lack of routine care and maintenance, such as lubrication and
         cleaning, as indicated in the instruction manual;
       - Inadequate utility service, failure of electrical or other energy
         supplies, incorrect physical environment, or other inadequate
         facilities or utilities as indicated in the instruction manuals
         and/or pre-installation instructions;
       - Chemical action or contamination;
       - Failure to maintain proper helium level in superconducting magnets;
b). Products items, parts, accessories, subassemblies, or components which
are expendable in normal use or operation of the instrument, or those of
limited life, such as but not limited to filters, glassware, glass
accessories, fuses, probe inserts, variable temperature dewars, and transfer
lines, unless specifically covered by an express warranty extended to the
customer by DALTONICS in writing.
4. The sole and exclusive remedy under this warranty shall be repair of
instrument malfunctions which in the sole opinion of DALTONICS are due or
traceable to defects in original materials or workmanship, or at DALTONICS
option, replacement of defective parts.
5. In-warranty repaired or replacement parts or products are covered by
warranty only for the remaining unexpired portion of the original warranty
period applicable to the repaired or replaced parts or products. Repair or
replacement of products or parts under warranty does not extend the original
warranty period.
6. After expiration of the applicable warranty period, DALTONICS will provide
service for which the customer shall be charged at DALTONICS then current
prices for parts, labor, and transportation.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

                    WARRANTY REPLACEMENT AND ADJUSTMENT

All claims under warranty must be made promptly after occurrence of
circumstances giving rise thereto and must be received within the applicable
warranty period by DALTONICS or its authorized representatives. Such claims
should include the product type and serial numbers, and a full description of
the circumstances giving rise to the claim. DALTONICS reserves the right in
its sole discretion to determine whether repair under valid warranty claims
shall be made by (a) sending a field service engineer to the site, (b) having
the customer send the defective part, assemble, or instrument to a service
shop or facility as authorized by DALTONICS, or (c) authorizing the customer
to return the same to DALTONICS. Before any products, parts, or assemblies
are sent to a service shop or facility or are returned to DALTONICS for
repair and/or adjustment, authorization from DALTONICS or its authorized
representative for the return and instructions as to how and where the same
should be shipped must be obtained. Any product, part, or assembly sent to an
authorized service shop or facility or returned to DALTONICS for examination
shall be sent prepaid via the means of transportation indicated as acceptable
by DALTONICS with all transportation at the expense of the customer.
DALTONICS reserves the right to reject any warranty claim not promptly
reported and any warranty claim on any item that has been altered or has been
shipped by non-acceptable means of transportation. When any product, part, or
assembly is sent to a service shop or facility or is returned to DALTONICS
for examination and inspection or for any other reason, the customer shall be
responsible for all damage resulting from improper packing or handling, and
for loss in transit, notwithstanding any defect or non-conformity in the
product part, or assembly. In all cases, DALTONICS has sole responsibility for
determining the cause and nature of failure, and DALTONICS determination with
regard thereto shall be final.

                           LIMITATION OF LIABILITY

Reasonable care must be used to avoid hazards. DALTONICS expressly disclaims
responsibility for loss or damage caused by use of its products other than
in accordance with proper operating procedures. IN NO EVENT SHALL DALTONICS
BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL OR RESULTING LOSS OR DAMAGE OF ANY
KIND, HOWEVER CAUSED. DALTONICS LIABILITY FOR DAMAGES SHALL NOT EXCEED THE
PAYMENT, IF ANY RECEIVED BY DALTONICS FOR THE UNIT OF PRODUCT OR SERVICE
FURNISHED OR TO BE FURNISHED, AS THE CASE MAY BE, WHICH IS THE SUBJECT OF
CLAIM OR DISPUTE.
All obligations of DALTONICS under this warranty shall cease in the event its
products or parts have been subject to accident, abuse, alteration, misuse or
neglect, or which have not been operated and maintained in accordance with
proper operating procedures.
All products and services provided within the scope of their warranty must be
provided through, or with the knowledge and approval of DALTONICS. DALTONICS
makes no warranty concerning services or components supplied through
unapproved sources. What constitutes an approved source shall be determined
by DALTONICS.
THIS WARRANTY IS EXPRESSLY IN LIEU OF AND EXCLUDES ALL OTHER EXPRESS OR
IMPLIED WARRANTIES, INCLUDING BUT NOT LIMITED TO WARRANTIES OF FITNESS FOR
PARTICULAR PURPOSE, USE, OR APPLICATION, AND ALL OTHER OBLIGATIONS OR
LIABILITIES ON THE PART OF DALTONICS, UNLESS SUCH OTHER WARRANTIES
OBLIGATIONS, OR LIABILITIES ARE EXPRESSLY AGREED TO IN WRITING.
Statements made by any person, including representatives of DALTONICS, which
are inconsistent or in conflict with the terms of this warranty, shall not be
binding upon DALTONICS unless reduced to writing and approved by an officer
of DALTONICS.
This warranty shall be construed under and governed by the law of the State
of Massachusetts. No action, regardless of form, arising out of, or in any
way connected with, the products or services furnished or to be furnished by
DALTONICS, may be brought by the customer more than one (1) year after the
cause of action has accrued.

                                ACCESSORIES

In lieu of the one (1) year period applicable to DALTONICS standard products,
accessories manufactured by DALTONICS are warranted to be free of defects in
material and workmanship for a period of ninety (90) days from the date of
shipment, or if DALTONICS specifically agrees in writing to provide
installation, ninety (90) days from the date of installation. All such
accessory warranties are limited in accordance with all the terms, condition,
and other provisions stated in this warranty.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

<Page>

------------------------------------------------------------------------------

                          GENERAL TERMS & CONDITIONS

A. GENERAL CONDITIONS

1. All quotations, shipments and services given and made by Bruker DALTONICS
are governed solely by the conditions and terms set forth in the quotation.
2. No additions to or modifications of any of the provisions upon the face or
reverse of this form shall be binding upon DALTONICS unless made in writing
and signed by a duly authorized representative.
3. In absence of written acceptance of these terms and conditions, an
acceptance of any goods or services, shipped or provided by DALTONICS based
on a purchase order received from purchaser shall constitute an acceptance of
these terms and conditions. The terms and conditions herein shall prevail as
against the terms and conditions of any purchase order.
4. The rights and obligations of the parties shall be governed in all
respects by the laws of the State of Massachusetts and the party shall submit
themselves to the jurisdiction of said State.
5. DALTONICS shall retain copyright, trademark, patent and proprietary rights
in all drawings, technical information, and know-how.
6. Documentation such as Software Listings, detailed Drawings and other
documentation normally not distributed may only be provided by DALTONICS
on the condition that the receiver of such documentation signs a
Confidentiality Agreement.
7. Clerical errors and mistakes of fact are subject to correction by
DALTONICS at any time.

B. PRICE AND QUOTATION

1. All quotations are firm for a period of 60 days from the date hereof,
unless specified in writing.
2. All prices are FOB shipping point unless otherwise stated. Responsibility
passes to purchaser upon delivery to Transportation Company and risk of
damage or loss following such delivery shall be purchasers.
3. Price quoted does not include City, State, or Federal Sales or similar
taxes. Purchaser shall report and pay all such taxes and hold DALTONICS
harmless therefrom.

C. ORDERS AND ORDER SPECIFICATIONS

1. Purchase orders are subject to acceptance by DALTONICS.
2. In a case where a new development is included in an order, or the
execution of any order depends upon successful completion of new development,
DALTONICS reserves the right to cancel such order, without incurring any
obligation to purchaser if such development cannot be completed successfully
in DALTONICS discretion. If the order is for the development of a single
unit, the foregoing shall apply and DALTONICS reserves the right to cancel
that part of the order which covers only the unit for which successful
development appears to be necessary.

D. DELIVERY AND SHIPMENT

1. Delivery time is computed from the date of acknowledgement of written
order.
2. DALTONICS shall not be liable for delivery delayed due to circumstances
beyond its control, including, but not limited to, fire, flood, war, labor
disputes, accidents or delay of carriers, sub contractors or suppliers.
3. Change of an order on request of purchaser after original order was
accepted by DALTONICS shall be subject to reacceptance. The originally quoted
delivery time may no longer be applicable. Should DALTONICS decline
acceptance of change order, the original order remains binding.
4. Cancellation of an order due to reasonable delay of delivery is excluded.
Any rights of purchaser for claims or compensation for damage or loss of any
kind whatsoever due to delay of delivery are excluded.
5. An order covering several independent functional units may be delivered
and invoiced in part as per functional unit and payment thereof shall be due
for such unit upon presentation of invoice.

E. TERMS AND PAYMENT

1. Invoices are due without deduction upon presentation.
Orders shipped and invoiced in separate parts shall be due upon receipt of
such parts. Failure to make payment when due on any one part shall relieve
DALTONICS of delivery of any remaining parts.
2. If Bank Guarantee or Bid Bond is requested the purchase set forth herein
shall be increased by the cost of such guarantee or bond.
3. Upon delivery or demonstration of specifications of the system DALTONICS
Bank Guarantee and/or Bid Bond are to be returned by purchasers.

F. TITLE

1. Title does not transfer to the Purchaser until final payment is received
in full by DALTONICS.

--------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.<Page>

                                                                EXHIBIT 10.30

                                Variagenics, Inc.
                                60 Hampshire St.
                               Cambridge, MA 02139

                          EXECUTIVE RETENTION AGREEMENT

CONFIDENTIAL

February 13, 2002

Taylor Jackson Crouch
83 Belcher Drive
Sudbury, MA 01776

Dear Taylor:

         This letter agreement (the "Amended and Restated Retention
Agreement") shall confirm our agreement with respect to additional
compensation you will receive in connection with your continued service as
the President and Chief Executive Officer of Variagenics, Inc. (the
"Company") during the [________________________] period which commenced on
October 11, 2001 and terminates on [________________] (the "Retention
Period") and amend and restate the Retention Agreement that was executed on
or about November 15, 2001 (the "November 15 Retention Agreement"). To the
extent the Amended and Restated Retention Agreement augments or differs from
the terms of your Employment Agreement dated March 18, 1999 (the "Employment
Agreement"), any of your Stock Option Agreements dated September 22, 1999,
February 11, 2000 or January 3, 2001 (collectively, the "Option Agreements")
or the November 15 Retention Agreement, those agreements are hereby amended
to such extent. The parties hereto acknowledge and agree that the November 15
Retention Agreement shall become null and void upon the execution of this
Amended and Restated Retention Agreement.

         In addition to the existing terms and conditions of your Employment
Agreement and Option Agreements, this Amended and Restated Retention
Agreement confirms that if you resign your employment at any time during the
Retention Period, so long as you provide a minimum of two (2) weeks advance
notice in writing, such resignation shall be treated as a resignation for
Good Reason, pursuant to the Employment Agreement, and any cash payments due
pursuant to Section 4(b)(i) of the Employment Agreement shall be paid in a
lump sum upon the termination of your employment with the Company. In
addition, because of the crucial role you have agreed to take on with respect
to certain critical objectives during the Retention Period, you shall receive
the compensation and benefits noted below, subject to the following
conditions:

CASH BONUSES

         Apart from continuing to be paid at the rate of $13,541.67 per
semi-monthly pay period as long as you remain employed by the Company, you
will be eligible to receive a total cash

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

<Page>

bonus of up $162,500 (the "Bonus Potential") if you attain the
following objectives during the Retention Period:

         (a) STRATEGIC RELATIONSHIPS--If a letter of intent is executed with
         respect to a collaborative transaction with a pharmaceutical or biotech
         company or a collaborative relationship with a research institution on
         a high-profile clinical study [_______________________________________
         ________________________________________________________], you shall
         receive a payment equal to one-sixth of the total Bonus Potential
         within thirty (30) days following execution of such letter of intent.
         If a second such letter of intent is executed, you shall receive an
         additional payment equal to one-sixth of the total Bonus Potential
         within thirty (30) days following execution of such letter of intent;

         (b) [________________________]--[____________________________________
         _____________________], you shall receive a payment equal to one
         third of the total Bonus Potential within thirty (30) days following
         execution of such letter of intent; and

         (c) BUDGET--If you present to the Board of Directors a reasonably
         detailed written budget that demonstrably will [____________________
         _______________________] and confer with the Board of Directors
         regarding the same in the context of a Board Meeting, you shall
         receive a payment equal to one third of the total Bonus Potential
         within thirty (30) days following such Board Meeting.

         Any cash payments shall be subject to customary federal, state and
local withholdings, and any Bonus Potential amounts actually earned during
the Retention Period that remain unpaid upon the expiration of the Retention
Period shall remain due and payable in accordance with the terms of preceding
paragraphs (a) - (c) in this Cash Bonuses section.

STOCK OPTIONS

         (a) EXISTING STOCK OPTIONS--Any stock options that were granted
         pursuant to the Option Agreements that have not vested as of the date
         of such resignation or termination shall vest and become exercisable
         upon the earlier of (i) [___________] or (ii) the date on which you
         resign your employment or the Company terminates your employment. To
         the extent permitted by law, such options shall remain exercisable for
         a period of one hundred eighty (180) days commencing on your final
         date of employment with the Company (so long as such exercise period
         does not exceed the expiration date of the particular options, as
         stated in the stock option agreement subject to which particular
         options were granted).

         (b) RETENTION STOCK OPTIONS--The Board of Directors, or their
         duly-authorized designees, shall grant you 175,500 stock options with
         an exercise price of $2.26 per share, subject to the terms of the
         Amended 1997 Employee, Director and Consultant Stock Option Plan and a
         stock option agreement on the form most recently approved by the Board
         of Directors, as qualified by this paragraph (the "Retention Options").
         If you are still employed by the Company on March 31, 2002 or your
         employment has been

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       2
<Page>

         terminated at the directive of the Board of Directors prior thereto,
         87,750 of such stock options shall vest and become exercisable as of
         that date. The remaining 87,500 shall vest and become exercisable as
         follows, assuming you remain employed by the Company on each vesting
         date: (i) 21,938 on April 30, 2002; (ii) 21,938 on May 31, 2002;
         (iii) 21,937 on June 30, 2002; and (iv) 21,937 on July 10, 2002. To
         the extent permitted by law, any such stock options shall remain
         exercisable for a period of one hundred eighty (180) days commencing
         on your final date of employment with the Company (so long as such
         exercise period does not exceed the expiration date of such options,
         as stated in the stock option agreement subject to which such options
         may be granted).

         (c) PERFORMANCE STOCK OPTIONS--If, at a time when you are still
         employed by the Company during the Retention Period, the Company (i)
         [_____________________]or (ii) [_______________________________] or
         [________________________________], the Board of Directors, or their
         duly-authorized designees, shall grant you 115,500 stock options with
         an exercise price of $2.26 per share, subject to the terms of the
         Amended 1997 Employee, Director and Consultant Stock Option Plan and a
         stock option agreement on the form most recently approved by the Board
         of Directors, as qualified by this paragraph. All such performance
         stock options shall vest and become exercisable upon the grant date.
         To the extent permitted by law, any such stock options shall remain
         exercisable for a period of one hundred eighty (180) days commencing
         on your final date of employment with the Company (so long as such
         exercise period does not exceed the expiration date of such options,
         as stated in the stock option agreement subject to which such options
         may be granted).

                  For the purpose of determining the period for which the any of
         the aforementioned options may be exercised, the expiration date of
         such options shall be deemed to be the expiration date set forth in the
         relevant agreement governing such options but disregarding the
         provisions for early termination of the options for any reason other
         than termination for "cause" as defined in such option agreement. In
         addition, the one hundred eighty (180) day period commencing on your
         final date of employment with the Company shall supersede any provision
         in the relevant agreement governing such options setting forth an
         exercise period for the options of less than one hundred eighty (180)
         days after your final date of employment with the Company.

                  Pursuant to the terms of the Amended 1997 Employee, Director
         and Consultant Stock Option Plan, you will be permitted to exercise the
         options noted above by using a cashless exercise program.

         All shares of the Company's stock owned by you shall be subject to any
restrictions imposed by law, and, [___________________________________________
______________________________________________________________]

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       3
<Page>

NON-COMPETITION

         You hereby agree that the companies set forth on SCHEDULE A to this
Amended and Restated Retention Agreement, together with their respective
affiliates, successors and related entities, shall be the only entities to be
considered a Competing Business for purposes of Section 5 of the Employment
Agreement.

EXPENSES

         The Company shall reimburse you for up to $5,000 in legal fees
relating to the negotiation of the November 15 Retention Agreement, within
thirty (30) days following presentation of appropriate invoices to Martin
Vogelbaum.

RELEASE AND WAIVER OF CLAIMS

         Your receipt of any cash, stock options or expense reimbursements
pursuant to the terms of the Amended and Restated Retention Agreement is
conditioned on your execution of a full and complete release and waiver of
claims with respect to the Company, its directors, officers and shareholders
(and its and their successors and assigns) in a form satisfactory to (and
provided by) the Company upon the earlier of (i) [_______________] or (ii)
the date of the termination of your employment with the Company for any
reason. A current example of a full and complete release is attached hereto
as Exhibit A for your review. Failure to execute and return such release and
waiver of claims to the Company within twenty-one (21) days of receipt, shall
subject any stock options granted hereunder to forfeiture and shall require
you to repay any cash payments provided hereunder upon the expiration of such
twenty-one (21) day period.

DISPUTE RESOLUTION

         To the extent that any disputes regarding this Amended and Restated
Retention Agreement may arise, they shall be resolved in accordance with the
terms of Section 10 of the Employment Agreement.

         We hope that you appreciate the unique nature of this arrangement
and we are pleased to recognize the important role we anticipate you will
play during the Retention Period. In order to accept this offer, you must
execute this letter where provided below and return it to Martin Vogelbaum,
by no later than February __, 2002.

                                       VARIAGENICS, INC.

                                       By:  /s/ Martin A. Vogelbaum
                                          --------------------------------
                                          Martin A. Vogelbaum
                                          Director

ACCEPTED AND AGREED:

By:  /s/ Taylor J. Crouch
   ---------------------------
Date:  2/13/02
     ----------------------

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       4
<Page>

                                     RELEASE

         You hereby agree and acknowledge that by signing this Release, you
are waiving your right to assert any form of legal claim against Variagenics,
Inc. ("Variagenics" or the "Company")(1) whatsoever for any alleged action,
inaction or circumstance existing or arising from the beginning of time
through the date on which you sign this Release. Your waiver and release
herein is intended to bar any form of legal claim, charge, complaint or any
other form of action (jointly referred to as "Claims") against Variagenics
seeking any form of relief including, without limitation, equitable relief
(whether declaratory, injunctive or otherwise), the recovery of any damages
or any other form of monetary recovery whatsoever (including, without
limitation, back pay, front pay, compensatory damages, emotional distress
damages, punitive damages, attorneys fees and any other costs) against
Variagenics for any alleged action, inaction or circumstance existing or
arising through the date on which you sign this Release.

         Without limiting the foregoing general waiver and release, you
specifically waive and release Variagenics from any Claims arising from or
related to your employment relationship with the Company or the termination
thereof, including without limitation:

         (i)      Claims under any local, state, federal or foreign
                  discrimination, fair employment practices or other employment
                  related statute, regulation or executive order (as they may
                  have been amended through the date on which you sign this
                  Release) prohibiting discrimination or harassment based upon
                  any protected status including, without limitation, race,
                  religion, citizenship, national origin, age, gender, genetic
                  carrier status, marital status, disability, veteran status or
                  sexual orientation. Without limitation, specifically included
                  in this paragraph are any Claims arising under the federal Age
                  Discrimination in Employment Act, the Older Workers Benefit
                  Protection Act, the Civil Rights Acts of 1866 and 1871, Title
                  VII of the Civil Rights Act of 1964, the Civil Rights Act of
                  1991, the Equal Pay Act, the Immigration Reform and Control
                  Act, the Americans With Disabilities Act and any similar
                  local, state, federal or foreign statute or law.

         (ii)     Claims under any other local, state, federal or foreign
                  employment related statute, regulation or executive order (as
                  they may have been amended through the date on which you sign
                  this Release) relating to wages, hours or any other terms and

----------------
(1)   For the purposes of this Section the parties agree that the phrase,
"Variagenics, Inc.", shall include Variagenics, Inc., its divisions,
affiliates, parents and subsidiaries, and its and their respective officers,
directors, employees, agents and assigns.

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       5
<Page>

                  conditions of employment. Without limitation, specifically
                  included in this paragraph are any Claims arising under the
                  Fair Labor Standards Act, the Family and Medical Leave Act of
                  1993, the National Labor Relations Act, the Employee
                  Retirement Income Security Act of 1974, the Consolidated
                  Omnibus Budget Reconciliation Act of 1985 ("COBRA") and any
                  similar local, state, federal or foreign statute or law.

         (iii)    Claims under any local, state, federal or foreign common law
                  theory including, without limitation, wrongful discharge,
                  breach of express or implied contract, promissory estoppel,
                  unjust enrichment, breach of a covenant of good faith and fair
                  dealing, violation of public policy, defamation, interference
                  with contractual relations, intentional or negligent
                  infliction of emotional distress, invasion of privacy,
                  misrepresentation, deceit, fraud or negligence.

         (iv)     Claims under any local, state or federal securities law,
                  including, without limitation, the Securities Act of 1933, as
                  amended, the Securities Exchange Act of 1934, as amended, and
                  any Massachusetts, Delaware or other state or local securities
                  statutes and regulations.

         (v)      Any other Claim arising under local, state or federal law.

         You acknowledge and agree that but for providing this waiver and
release, you would not be receiving the consideration provided to you by the
Company through the Retention Agreement between you and the Company.

         Because you are more than forty (40) years of age, you have specific
rights under the Older Workers Benefits Protection Act ("OWBPA"), which
prohibits discrimination on the basis of age, and that the releases set forth
herein are intended to release any right that you may have to file a claim
against the Company alleging discrimination on the basis of age.

         It is the Company's desire and intent to make certain that you fully
understand the provisions and effects of this letter. To that end, you have
been encouraged and given the opportunity to consult with legal counsel for
the purpose of reviewing the terms of this Release. Consistent with the
provisions of OWBPA, your signature below confirms that the Company has
provided you with at least twenty-one (21) days in which to consider and
accept the terms of this Release. In addition, you may rescind your assent to
this Agreement if, within seven (7) days after you sign this Agreement, you
deliver a written

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       6
<Page>

notice of rescission to the Company's Board of Directors. To be effective,
such rescission must be in writing and must be hand-delivered or post-marked
within the seven (7) day period and sent by certified mail to Variagenics in
care of Martin Vogelbaum.

Confirmed and Agreed:                  Variagenics, Inc.

__________________________________     By: _______________________________
Taylor J. Crouch

Dated: _____________________, 2002     Dated: ______________________, 2002

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       7
<Page>

                                   Schedule A

                              COMPETING BUSINESSES

                                   [________]

                                     [____]

                                     [____]

                                   [________]

                                     [____]

                                     [____]

                                   [________]

                                     [____]

                                     [____]

                                     [____]

                                   [________]

--------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of
1934.

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00036-of-00352.parquet"}]]